-transparent.png){kind=logo}
Female rats bearing N-nitrosomethylurea-induced mammary carcinomas were treated with pergolide mesylate to suppress serum prolactin. The drug was given alone, or with somatostatin, 20 micrograms/hr delivered by osmotic minipump for 7 days to suppress serum growth hormone. Tumour regressions did not occur with pergolide alone, but did so promptly in all of 5 rats when growth hormone levels were also suppressed by somatostatin. A potent long-acting agonistic analogue of somatostatin, L362,823 produced similar tumour regressions at a dose of 5 micrograms/hr when given with pergolide, but was ineffective alone. This dose completely prevented the episodic release of pituitary growth hormone.
D P Rose, and
M Gottardis, and
J J Noonan
May 1978,
The Journal of endocrinology,
D P Rose, and
M Gottardis, and
J J Noonan
April 1975,
Cancer research,
D P Rose, and
M Gottardis, and
J J Noonan
January 1982,
Cancer research,
D P Rose, and
M Gottardis, and
J J Noonan
June 1983,
Cancer research,
D P Rose, and
M Gottardis, and
J J Noonan
August 1976,
Experientia,
D P Rose, and
M Gottardis, and
J J Noonan
January 1986,
Cell biology international reports,
D P Rose, and
M Gottardis, and
J J Noonan
September 2015,
BMC veterinary research,
D P Rose, and
M Gottardis, and
J J Noonan
January 1977,
Acta endocrinologica,
D P Rose, and
M Gottardis, and
J J Noonan
March 1972,
Endocrinology,
D P Rose, and
M Gottardis, and
J J Noonan
May 1973,
Endocrinology,
